Anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis: A case report.

A 56-year-old male presented to the clinic for follow-up of severe, longstanding hidradenitis suppurativa. On physical examination, there was a linear Blaschkoid distribution of erythematous scaly papules extending from the left upper arm toward the scapular mid-back region. A clinical diagnosis of linear psoriasis was made, and the patient's dosage interval of infliximab was decreased to every 6 weeks. The patient was offered Betamethasone diproprionate/calcipotriol (Enstilar) topical foam to use daily which demonstrated efficacy in clearing 90% of the affected areas. This case illustrates the potential for Betamethasone diproprionate/calcipotriol (Enstilar) topical foam use as a treatment approach for anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis. At present there is no consensus on linear psoriasis pathogenesis or best treatment approach, therefore, more research is needed to understand its pathogenesis and establish management guidelines.